Literature DB >> 10625494

Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line.

B Ogretmen1, A R Safa.   

Abstract

In this report, the molecular mechanisms involved in the overexpression of MDR1 mRNA in the multidrug resistant variant of the HL60 human acute myeloid leukemia cell line, HL60/VCR, were investigated. RT-PCR and nuclear run-on assays revealed that the expression of MDR1 mRNA is regulated by increased transcriptional initiation in HL60/VCR cells. Transient transfections with a 241 bp MDR1 promoter (spanning the -198 to +43 region) DNA fragment/pGL3-basic plasmid construct resulted in about 6-fold increased luciferase activity in HL60/VCR but not in HL60 cells. Moreover, ds CAAT-oligomer from the MDR1 promoter cloned upstream of the SV-40 promoter in the pGL3-promoter plasmid caused about a 7-fold increase in luciferase activity compared with plasmid constructs containing CAAT-deleted, GC-box, and nonspecific oligomers in HL60/VCR transfectants. These results were confirmed by transfecting HL60/VCR cells with the pGL3-basic plasmid containing a 237 bp mutated MDR1 proximal promoter lacking the CAAT sequence in which no change in luciferase activity was observed. However, a 5-6-fold increase in luciferase activity was measured in these cells when transfected with the wt MDR1 promoter DNA/pGL3-basic plasmid constructs. These results show that the CAAT-region is involved in upregulating the MDR1 promoter in HL60/VCR cells. A nuclear factor binding to the CAAT-region of the MDR1 promoter specifically was detected in electrophoretic mobility shift assays (EMSAs) in HL60/VCR but not in HL60 extracts. Two MDR1 promoter-associated polypeptides with molecular masses of about 130 and 162 kDa were identified in HL60/VCR cells by electroelution, specific DNA-affinity chromatography, and silver staining. Interestingly, cross-linking and Southwestern analysis indicate that only the 130 kDa protein, which we refer to as MDR1-promoter enhancing factor 1 (MEF1), has a strong DNA-binding ability, interacting with the 5'-GTCAATCC-3' element of the MDR1 promoter, as determined by DNase I protection assay. These data reveal that MEF1 upregulates the MDR1 promoter activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625494     DOI: 10.1021/bi991943f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Authors:  Su-Fern Tan; Wendy Dunton; Xin Liu; Todd E Fox; Samy A F Morad; Dhimant Desai; Kenichiro Doi; Mark R Conaway; Shantu Amin; David F Claxton; Hong-Gang Wang; Mark Kester; Myles C Cabot; David J Feith; Thomas P Loughran
Journal:  J Lipid Res       Date:  2019-04-08       Impact factor: 5.922

3.  Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function.

Authors:  Iyad Sultan; Can E Senkal; Suriyan Ponnusamy; Jacek Bielawski; Zdzislaw Szulc; Alicja Bielawska; Yusuf A Hannun; Besim Ogretmen
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

4.  The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Authors:  Trevor J Mathias; Karthika Natarajan; Suneet Shukla; Kshama A Doshi; Zeba N Singh; Suresh V Ambudkar; Maria R Baer
Journal:  Invest New Drugs       Date:  2015-01-20       Impact factor: 3.850

5.  New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.

Authors:  Stéphane Labialle; Guila Dayan; Landry Gayet; Dominique Rigal; Joël Gambrelle; Loris G Baggetto
Journal:  Nucleic Acids Res       Date:  2004-07-22       Impact factor: 16.971

6.  TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.

Authors:  Ching-Huang Wu; Ching-Hai Kao; Ahmad R Safa
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

7.  Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI.

Authors:  Mi-Ran Choi; Farhad Najafi; Ahmad R Safa; Hannes C A Drexler
Journal:  Biochem Pharmacol       Date:  2008-04-07       Impact factor: 5.858

8.  The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Authors:  Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Mehmet Burcu; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Biochem Pharmacol       Date:  2012-12-19       Impact factor: 5.858

9.  Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells.

Authors:  Marisa Meyers-Needham; Suriyan Ponnusamy; Salih Gencer; Wenhui Jiang; Raquela J Thomas; Can E Senkal; Besim Ogretmen
Journal:  EMBO Mol Med       Date:  2011-12-19       Impact factor: 12.137

10.  Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells.

Authors:  Yuan Zhang; Cheng-wei Wang; Zhi-gang Wang; Dao-xin Ma; Shun Pan; Shu-gan Zhu; Feng Li; Bo Wang
Journal:  J Neurooncol       Date:  2007-06-27       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.